biotech Value proposition
Antibody for Therapy
AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers.
AbTx platform is developing mAb innovative enzymatic conjugation.
Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs).
ADC, Oncology, and drug develomentOriginal language
Antibody for Therapy
AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers.
AbTx platform is developing mAb innovative enzymatic conjugation.
Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs).
AbTx - Antibody for Therapy
Embrace the future of ADC technology. Development of innovative enzymatic conjugaison to bring the next generation of treatments.
https://abtx-bio.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | SATT Aquitaine Science Transfert | Other 10 Mar 2025 | | |
 Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Agence Economique Régionale Bourgogne-Franche-Comté - AER BFC / AERBFC Government Administration | Other 4 Feb 2025 | | |
 Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Other 4 Feb 2025 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 30 Nov 2024 | | |
 DECA-BFC Startup accelerator & VC | DECA-BFC Startup accelerator & VC | Other 13 Mar 2024 | | |
 SAYENS Research, Startup accelerator & VC, Research Services | SAYENS Research, Startup accelerator & VC, Research Services | Other 20 Dec 2024 | | |